retatrutide phase 3 2025 triple agonist glp-1 gip glucagon 10mg | GLP-1/GIP/Glucagon Retatrutide Phase 3: 28.7% Weight

2014;16(12):1180-1191.[DOI] 74

Disclosure of interest: Dr Pavan Pai: Nothing to disclose E-Posters - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.02 - SECONDARY PREVENTION P2510 - ESOC25-1100 PHYSICAL ACTIVITY FOR SECONDARY PREVENTION - EXPLORING FACTORS INFLUENCING PARTICIPATION AND ENGAGEMENT IN POST-STROKE EXERCISE REHABILITATION Emma Martin 1 , Trudi Cameron 2 , Kate Radford 2,3 1 University College London, London, United Kingdom, 2 Centre for Rehabilitation and Ageing Research, School of Medicine, University of Nottingham, Nottingham, United Kingdom, 3 NIHR Nottingham Biomedical Research Centre, Nottingham, United Kingdom Background and Aims: Secondary prevention benefits of post-stroke exercise are well established, however participation remains low

At the gene level, it modulates roughly 4,000 human genes, activating around 1,600 involved in repair and regeneration while suppressing age-related inflammatory pathways

GLP-1-based therapies carry recognised class-effect risks including pancreatitis, gallbladder disease, and gastrointestinal adverse effects requiring urgent medical attention if they occur